搜索
Current location:
Homepage
/
/
/
/
Ready-to-use multiplex immunofluorescence panel
技术平台

Ready-to-use multiplex immunofluorescence panel

Product Description
Case Analysis
Result display
Sample delivery
Q&A

Product introduction

This product is used for tumor immune microenvironment assessment and clinical development and translational research of tumor immune drugs, covering multiple dimensions such as tumor immunotherapy targets and tumor immune cells. Through high specificity multiplex fluorescence staining, spectral imaging and high throughput image analysis technologies, we can accurately capture tumor microenvironment data to empower anti-tumor drug development.

 

 

Sample image of product BB02

 

 

Service products and cycle

Product Number    

Indicators Tissue Phenotype

Data Analysis

Lead time

BB01

CD3、CD20、CD68、
CD163、Ki67、pan-CK、DAPI

T cells, B cells, M1 macrophages, M2 macrophages

Standard analysis.

1. tissue partitioning: tumor and interstitial.

2. cell typing: defining the different cell types separately and calculating the number, density and percentage of cells.

Extended analysis.

1. Evaluation of expression indicators TPS and CPS;

2  statistics on the number, density, and percentage of immune checkpoint molecules expressed in different types of cells.

3. spatial analysis.

 

10 working days

BB02

CD4、CD8、FOXP3、
PD-1、PD-L1、pan-CK、DAPI

Helper T cells, killer T cells

BB03

CD8、CD68、CD56、
PD-1、PD-L1、pan-CK、DAPI

Treg, immune checkpoint

killer T cells, total macrophages,

Depleted T cells, NK cells, immune checkpoints

BB04

PD-1、PD-L1、CD68、
CD8、CD163、pan-CK、DAPI

M1 macrophages, M2 macrophages, killer T cells, immune checkpoints

BB05

CD3、CD4、CD20、
CD56、FOXP3、pan-CK、DAPI

depleted T cells, immune checkpoints

total T cells, helper T cells.

B cells, NK cells, Treg

BB06

CD4、CD8、GZMB、
Ki67、FOXP3、pan-CK、DAPI

depleted T cells, immune checkpoints

total T cells, helper T cells.

B cells, NK cells, Treg

BB07

CD11c、CD20、CD68、
CD163、CD3、pan-CK、DAPI

tertiary lymphoid structures, B cells, T cells, and

Germinal center activated B cells, follicular dendritic cells

Tertiary lymphoid structures, B cells, killer T cells

BB08

CD20、CD21、CD23、
CD3、Ki67、pan-CK、DAPI

tertiary lymphoid structures, B cells, T cells, and

Germinal center activated B cells, follicular dendritic cells

BB09

CD20、CD23、CD8、
PD-1、PD-L1、pan-CK、DAPI

Tertiary lymphoid structures, B cells, killer T cells

follicular dendritic cells, depleted T cells, immune checkpoints

BB10

PD-1、CD8、CD68、
CD56、FOXP3、pan-CK、DAPI

killer T cells, total macrophages,

NK cells, Treg, immune checkpoints

 

Article: Predicting response to PD-1 blockade in cutaneous T-cell lymphoma (CTCL) by immune cell distribution

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Publication date: November 2021

Journal: Nature communications (IF=17.694)

Published by: Stanford University School of Medicine, Harvard Medical School, et al.

Article Overview

The article is a joint study published by Stanford University School of Medicine, Harvard Medical School and others. The study focused on the differential effect of PD-1 immunotherapy in patients with cutaneous T-cell lymphoma (CTCL). Traditional assays such as immunohistochemistry (IHC), gene expression and mass spectrometry were unable to find appropriate predictive biomarkers. By thinking out of the box, the authors suggested that since the differences could not be found in quantity, it might be found in spatial distribution. The authors assessed the location of CD4+ T cells with Treg and tumor cells by multiplex immunofluorescence assay technique and established a spatial scoring mechanism for predicting clinical immunotherapy efficacy.

 

conceptual design

 

 

Cell domain analysis

 

 

Space score

Result display

Notices of samples delivery

1. Sample information

(1) Tissue origin: All specimens to be tested should provide accurate information about tissue type (e.g. melanoma, non-small cell lung cancer, colon cancer) and species (e.g. human origin, mouse).

(2) Labeling number: Each slide or wax block should be labeled with a clearly identifiable unique number, and TMA slides should be provided with the chip layout and number.

2. Sample types

(1) Formalin-fixed wax blocks or slides, large pieces of tissue or TMA are acceptable.

(2) The sealing wax should not have obvious breakage.

(3) For slide samples, the tissue needs to fit snugly on the slide, avoiding folds, and the slide should not be broken, scratched or stained.

(4) The tissue should contain a minimum of more than 1000 cells.

3. Wax block requirements

(1) The wax block should be embedded with solid tumor tissue; necrotic tumor tissue, needle punctures tissue, and cytospin samples are not acceptable.

(2) Tissue should be fixed with 10% neutral formalin or 4% paraformaldehyde, with a fixation time of 18~24 hours.

(3) Samples fixed by other methods need to be clearly indicated.

(4) The wax block box should have clear and unambiguous number information (please do not just label with a simple number such as 1, 2, 3).

(5) Wax blocks should be stored in a sealed bag with the block number indicated.

4. Slides requirements

(1) The thickness of the slides should be about 3~4um. Please use anti-dislodging slides! (Very important)

(2) It is recommended that the slides should be prepared within one week after fixation.

(3) Prepare at least 2 slides for one sample to be tested.

(4) Do not add any adhesive during water bath.

(5) The sample should be placed in the middle of the slide.

(6) Place the slide upright on absorbent paper to remove water,  remove water droplets by tapping slightly. Please do not wipe the slide with paper!

(7) Place the slide on a 45 degree hot plate for 30 min (naturally drying process should not be less than 1 hour).

(8) Slides must be completely dry before transportation.

(9) Each slide must be clearly numbered!

(10) Slides must be placed in a special slide box with the number and inatitution name clearly marked on the box.

(11) If slides have obvious folds and creases.

5. TMA Requirements

(1) Provide a description of the TMA chip point map (several rows and columns).

(2) The TMA slides must be matched with the chip point diagram.

(3) Minimum core point diameter >0.6mm.

(4) TMA core points must not overlap.

(5) Test slides derived from the same TMA wax block (usually incomplete slides from TMA sectioning for pre-experimental testing) need to be provided.

6. Transportation requirements

(1) Samples from different project groups can be transported together, but each group must be placed in a separate package and be clearly marked with: project number (customer order number) \ list of sample numbers \ contact person \ mobile phone number.

(2) Wax block: placed in a separate sealing pocket.

(3) Slides: placed inside the slide box, labeled clearly.

(4) TMA: placed inside the slide box with the instructions of the slide number.

(5) Please use an efficient courier channel such as S.F. to avoid samples being trasnported for a long time.

 

Stay tuned for further updates...

Follow us

Link: